CASI Pharmaceuticals (CASIF) Non Operating Interest Expenses (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Non Operating Interest Expenses came in at -$1.5 million in Q4 2025, down 417.89% on a YoY basis from $464304.6 in Q4 2024, and down 656.92% quarter-over-quarter from -$195000.0 in Q3 2025.
Powered by 
Analysis
CASI Pharmaceuticals (CASIF) Non Operating Interest Expenses (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has reported Non Operating Interest Expenses for 2 consecutive years, with -$1.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Interest Expenses fell 417.89% year-over-year to -$1.5 million; the trailing twelve-month figure through Dec 2025 stood at -$2.1 million (down 142.48% YoY), and the FY2025 full-year result was -$840000.0, up 3.56% from the prior year.
- Non Operating Interest Expenses eased to -$1.5 million in Q4 2025 per CASIF's latest filing, from -$195000.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at -$190000.0 in Q2 2024 and bottomed at -$1.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 281.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -462.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -333.60 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 23.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 582,000.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 2.90 Mn |
| 10 | CASI Pharmaceuticals | 2.39 Mn | -1.38 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -1.48 Mn |
| Sep 30, 2025 | -195,000.00 |
| Jun 30, 2025 | -244,000.00 |
| Mar 31, 2025 | -197,000.00 |
| Dec 31, 2024 | -285,000.00 |
| Sep 30, 2024 | -204,000.00 |
| Jun 30, 2024 | -190,000.00 |
| Mar 31, 2024 | -192,000.00 |